Trabectedin as a single agent and in combination with pegylated liposomal doxorubicin - activity against ovarian cancer cells.Over 225 000 new cases of ovarian cancer are diagnosed each year.  One of the most promising antineoplastic agents is trabectedin (Yondelis), derived from the marine tunicate Ecteinascidia turbinata, approved by the European Union in July 2007 for the treatment of soft-tissue sarcomas.  Trabectedin shows anti-tumour activity in vitro and in vivo in ovarian, breast, prostate, renal, melanoma and non-small cell lung cancer cell lines.  Trabectedin in combination with pegylated liposomal doxorubicin demonstrates synergistic antineoplastic activity.
trabectedin
One of the most promising antineoplastic agents is trabectedin (Yondelis), derived from the marine tunicate Ecteinascidia turbinata, approved by the European Union in July 2007 for the treatment of soft-tissue sarcomas. 
Yondelis
Trabectedin as a single agent and in combination with pegylated liposomal doxorubicin - activity against ovarian cancer cells.Over 225 000 new cases of ovarian cancer are diagnosed each year.  One of the most promising antineoplastic agents is trabectedin (Yondelis), derived from the marine tunicate Ecteinascidia turbinata, approved by the European Union in July 2007 for the treatment of soft-tissue sarcomas.  Trabectedin shows anti-tumour activity in vitro and in vivo in ovarian, breast, prostate, renal, melanoma and non-small cell lung cancer cell lines.  Trabectedin in combination with pegylated liposomal doxorubicin demonstrates synergistic antineoplastic activity.
trabectedin
Trabectedin as a single agent and in combination with pegylated liposomal doxorubicin - activity against ovarian cancer cells.Over 225 000 new cases of ovarian cancer are diagnosed each year.  One of the most promising antineoplastic agents is trabectedin (Yondelis), derived from the marine tunicate Ecteinascidia turbinata, approved by the European Union in July 2007 for the treatment of soft-tissue sarcomas.  Trabectedin shows anti-tumour activity in vitro and in vivo in ovarian, breast, prostate, renal, melanoma and non-small cell lung cancer cell lines.  Trabectedin in combination with pegylated liposomal doxorubicin demonstrates synergistic antineoplastic activity.
trabectedin
Trabectedin as a single agent and in combination with pegylated liposomal doxorubicin - activity against ovarian cancer cells.Over 225 000 new cases of ovarian cancer are diagnosed each year.  One of the most promising antineoplastic agents is trabectedin (Yondelis), derived from the marine tunicate Ecteinascidia turbinata, approved by the European Union in July 2007 for the treatment of soft-tissue sarcomas.  Trabectedin shows anti-tumour activity in vitro and in vivo in ovarian, breast, prostate, renal, melanoma and non-small cell lung cancer cell lines.  Trabectedin in combination with pegylated liposomal doxorubicin demonstrates synergistic antineoplastic activity.
trabectedin
Trabectedin as a single agent and in combination with pegylated liposomal doxorubicin - activity against ovarian cancer cells.Over 225 000 new cases of ovarian cancer are diagnosed each year.  One of the most promising antineoplastic agents is trabectedin (Yondelis), derived from the marine tunicate Ecteinascidia turbinata, approved by the European Union in July 2007 for the treatment of soft-tissue sarcomas.  Trabectedin shows anti-tumour activity in vitro and in vivo in ovarian, breast, prostate, renal, melanoma and non-small cell lung cancer cell lines.  Trabectedin in combination with pegylated liposomal doxorubicin demonstrates synergistic antineoplastic activity.
trabectedin